BE XR OD vs IR BID - which Cmax for IR? [Regulatives / Guidelines]

posted by jag009  – NJ, 2020-05-11 08:29 (942 d 17:26 ago) – Posting: # 21417
Views: 3,083

❝ I would like to have the help of the forum participants on a tricky question, ie which IR Cmax should be considered to assess the potential bioequivalence between an IR formulation administered BID and an XR formulation administered OD on day 1 and at steady-state. This is for a submission to FDA.


Not sure if the following will answer your Q exactly and whether it still exists on FDA website (or they blacked out the results):
Look for Ultram ER at [email protected]
Similar approach (Don't ask how I know :))

J

Complete thread:

UA Flag
Activity
 Admin contact
22,436 posts in 4,696 threads, 1,599 registered users;
16 visitors (0 registered, 16 guests [including 10 identified bots]).
Forum time: 00:55 CET (Europe/Vienna)

Meta-analysis – A technique for adding apples and pears
together to produce turkeys.    Stephen Senn

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5